30
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory GERD symptoms in connective tissue disease patients

, , , , , , , & show all
Pages 357-364 | Received 13 Jan 2012, Accepted 23 Apr 2012, Published online: 02 Jan 2014

REFERENCES

  • Ling TC, Johnston BT. Esophageal investigations in connective tissue disease which tests are most appropriate? J Clin Gastro-enterol. 2001;32:33–6.
  • Patti MG, Gasper WJ, Fisichella PM, Nipomnick I, Palazzo F. Gastroesophageal reflux disease and connective tissue disorders: pathophysiology and implications for treatment. J Gastrointest Surg. 2008;12:1900–6.
  • Daruwala C, Mercogliano G, Harder TP. Gastrointestinal mani-festations of systemic lupus erythematosus and scleroderma. Clin Med Insights Gastroenterol. 2009;2:7–12.
  • Chong VH, Wang CL. Higher prevalence of gastrointestinal symptoms among patients with rheumatic disorders. Singapore Med J. 2008;48:419–24.
  • Ebert EC. The gastrointestinal complications of myositis. Ali-ment Pharmacol Ther. 2010;31:359–65.
  • Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifes-tations of systemic sclerosis. Dig Dis Sci. 2008;53:1163–74.
  • Volter F, Fain 0, Mathieu E, Thomas M. Esophageal function and Sjögren's syndrome. Dig Dis Sci. 2004;49:248–53.
  • Marshall JB, Kretschmar JM, Gerhardt DC, Winship DH, Winn D, Treadwell EL, et al. Gastrointestinal manifestations of mixed connective tissue disease. Gastroenterology. 1990;98:1232–8.
  • Fujiwara Y, Arakawa T. Epidemiology and clinical characteris-tics of GERD in the Japanese population. J Gastroenterol. 2009;44:518–34.
  • Hatlebakk JG, Katz PO, Camacho-Lobato L, Cate11 DO. Proton pump inhibitors: better acid suppression when taken before ameal than without a meal. Aliment Pharmacol Ther. 2000;14: 1267–72.
  • Morise K, Iizuka A, Inagaki T, Sugie M, Matsunaga Y, Nakata K, et al. Clinical effect of omeprazole, a gastric proton pump inhibitor-comparative study on morning dose and bed-time dose in the treatment of peptic ulcer. Yakuri to Rinsyo. 1988;16: 593–608.
  • Shinomura K, Kaneyama S, Miyazaki Y, Okuda S, Iiishi H, Himeno S, et al. Mod Phys. 1994;14:69-84.
  • Tateno M, Nakamura M. Phase I study of lansoprazole (AG-1749) antiulcer agent-capsule form-. Rinsyo Iyaku. 1991;7: 51–62.
  • Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32:466–73.
  • Kusano M, Shimoyama Y, Sugimoto S, Kawamura 0, Maeda M, Minashi K, et al. Development and evaluation of FSSG: fre-quency scale for the symptoms of GERD. J Gastroenterol. 2004;39: 888–91.
  • Dimenas E, Glise H, Hallerback B, Hemqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–52.
  • Kinoshita Y, Ishihara S. Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux dis-ease in Asia. Therap Adv Gastroenterol. 2008;1:191–9.
  • Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309.
  • Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibi-tors: a randomized three-way cross over study. Aliment Phar-macol Ther. 2006;24:1445–51.
  • Xie HG, Stein CM, Kim RB, Wilikinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of 5-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharma-cogenetics. 1999;9:539–49.
  • Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriy-ama S, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.